CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock News
NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD
CYCCP Latest News, Press Relases and Analysis
Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split
Cyclacel Pharmaceuticals (CYCC) announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L876. Published first on TheFly – the ultimate source for real-t
Cyclacel Pharmaceuticals Announces Stock Split
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
CYCLACEL PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
Mentions: CYCC
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a...
Mentions: CYCC
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a...
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a...
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (
Mentions: CYCC
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Mentions: CYCC
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Mentions: CYCC
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities...
Mentions: CYCC
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities -
Mentions: CYCC
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities ...
Mentions: CYCC
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel to participate at the H.C. Wainwright 26th Annual Global Investment Conference...
Mentions: CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Mentions: CYCC
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Cyclacel timely appeals against Nasdaq delisting letter. Delisting stayed until Nasdaq hearing panel determination...
Mentions: CYCC
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Delisting or suspension action stayed pending the issuance of a final decision
Mentions: CYCC
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy...
Mentions: CYCC